[doi: 10.5505/2017ichc.PP-235]
The effects of sunitinib on immunoreactivities of vimentin, E-cadherin and S100 in kidneys of the experimental Streptozotocin -induced mouse model
Saadet Özen Akarca Dizakar1, Hüseyin Aktuğ2, Fatih Oltulu2, Gülperi Öktem2, Altuğ Yavaşoğlu2, Eda Açıkgöz2, Gürkan Yiğittürk2, Kenan Demir2, Ayşegül Uysal22Department of Histology and Embryology, Ege University Medical Faculty, İzmir, TURKEY
Diabetes mellitus (DM) is a chronic disease and has negative effects on most of system and organs including kidney. Sunitinib is an oral inhibitor of tyrosine kinase that cause sunitinib-induced hypoglycemia. The aim of this study was to investigate the possible effects of tyrosine kinase inhibitor sunitinib on the kidney of Streptozotocin (STZ) -induced type 1 diabetic mice.
In this study, twenty- eight CD 1 type male mice were used and equally divided into four groups (n=7). Type I diabetes was induced by intraperitoneal (i.p.) administration STZ. Fourteen mice with normal blood glucose levels were included in control group (Group 1) and control treated sunitinib group (Group 2). Mice with ≥250 mg/dL blood glucose levels were considered as diabetic with saline group (Group 3) and sunitinib- treatment group (Group 4). After 8 week kidneys were removed. The immunoreactivities of vimentin, E-cadherin and S100 and were evaluated by using immunohistochemical procedure. Immunostaining of vimentin, E-cadherin and S100 were situated in both of the glomeruli and tubules of the kidney. Our results showed that the number of vimentin and E-cadherin positive glomeruli and tubules were increased after sunitinib treatment, compared to saline-treated diabetic mice. However, vimentin labeled tubules, were decreased in the sunitinib treatment group compared to diabetic+saline groups. There were no statistically significant differences the number of S100 positive tubules and glomeruli in the between group 3 and 4. In this study, we can conclude that the effect of sunitinib on the experimental diabetic mouse model are related to immunostaining of vimentin, E-cadherin and S100 in glomeruli and tubulus of kidney and sunitinib may have positive effect for treatment of renal damage from diabetic process.
figure
)
Vimentin, E-cadherin and S100 immunostaining in renal tissue. Magnification x400